Rauwolscine, [Methyl-³H]-, 250µCi (9.25MBq)

Rauwolscine acts as an α2-adrenergic receptor antagonist.

We offer both agonist and antagonist radioligands for autoradiographic visualization or performing saturation and competition assays to determine receptor expression levels (B_max), dissociation constants (K_d), association and dissociation rates (k_on and k_off), and inhibitor constants (K_i) for a variety of receptors. We develop our radioligands to the highest specific activity possible and provide high purity resulting in low non-specific binding products. Each of our ultra-pure radioligands is fully characterized for pharmacological action and validated in receptor binding assays.

Radiolabeled ligands remain the most sensitive method for probing receptor binding biology; yielding unprecedented sensitivity gives results that technicians and scientists can trust. For over 50 years, Revvity has been a leading supplier of New England Nuclear (NEN) radiochemicals, liquid scintillation cocktails, vials and nuclear counting detection instruments.

References for NET722:

1. T. Nakagawa, K. Nagayasu, N. Nishitani, H. Shirakawa, K. Sekiguchi, Y. Ikarashi, Y. Kase, S. Kaneko, Yokukansan inhibits morphine tolerance and physical dependence in mice: The role of α2A-adrenoceptor, Neuroscience, Volume 227, 2012, Pages 336-349.
2. Ignacio Javier Chiesa, Lilian Fedra Castillo, Isabel Alicia Lüthy, Contribution of α2-adrenoceptors to the mitogenic effect of catecholestrogen in human breast cancer MCF-7 cells, The Journal of Steroid Biochemistry and Molecular Biology, Volume 110, Issues 1–2, 2008, Pages 170-175.